Many cancer tablets and some infusions can irritate the liver, sometimes with no symptoms, so liver blood tests are taken before treatment and at set intervals after. A mild rise is watched, a larger one means a pause and often a lower dose, and a rise with jaundice usually means stopping. Yellow skin or eyes, dark urine or itching need a call to your cancer team straight away.
Liver injury from kinase inhibitors, CDK4/6 inhibitors, KRAS and IDH inhibitors and some antibody-drug conjugates can be silent and is then found only on blood tests. Each label sets its own schedule and its own thresholds, and the label of the drug being taken is the rule; the reader's own team's protocol comes first.
Monitoring schedules in the US labels read, after a baseline test: ribociclib every 2 weeks for the first 2 cycles, then at the start of each of the next 4 cycles; abemaciclib every 2 weeks for 2 months, then monthly for 2 months; tucatinib every 2 weeks for 2 months, then every 3 weeks throughout; pazopanib at weeks 3, 5, 7 and 9 and at months 3 and 4; sotorasib every 3 weeks for 3 months, then monthly; adagrasib monthly for 3 months; selpercatinib every 2 weeks for 3 months, then monthly; vorasidenib every 2 weeks for 2 months, then monthly for the first 2 years; ponatinib at least monthly; lapatinib every 4 to 6 weeks; trastuzumab emtansine and trabectedin before each dose. All except the trastuzumab emtansine sentence add 'as clinically indicated'.
When ALT or AST is confirmed above 3 times the upper limit of normal (ULN), the FDA guidance (written for trials) advises close observation at once: repeat tests two or three times a week, a history of other medicines, supplements and alcohol, and exclusion of viral hepatitis A to E, autoimmune and alcoholic hepatitis, fatty liver disease, ischaemia and biliary disease. AASLD 2023 recommends viral serology and liver imaging for all suspected cases. In its section on checkpoint inhibitors it adds that recent studies suggest drug injury accounts for only 30% of demonstrable liver injury in advanced cancer, the rest being metastases, sepsis and other causes.
Hold thresholds differ by label. Pazopanib continues through an isolated ALT of 3 to 8 times ULN with weekly tests and is withheld above 8 times. Abemaciclib is withheld for persistent or recurrent grade 2 or for grade 3 (more than 5 to 20 times ULN). Ribociclib is interrupted from grade 2 if the baseline was below grade 2. Sotorasib is withheld above 5 times ULN, or above 3 and up to 5 times with symptoms. Vorasidenib is withheld from grade 2. Grade 4 (more than 20 times ULN) ends treatment in the ribociclib, abemaciclib, tucatinib and vorasidenib labels.
ALT or AST above 3 times ULN with bilirubin above 2 times ULN and no cholestasis or other cause (a Hy's law case) is the stop signal: the FDA guidance puts the risk of death or transplant at roughly one tenth of such cases. Ribociclib, abemaciclib, tucatinib and pazopanib are stopped permanently; sotorasib and adagrasib are stopped if no other cause is found, and the trastuzumab emtansine dose table says the same (its warning section gives the stop without that condition); the vorasidenib label alone allows a reduced dose after recovery from a first occurrence.
Corticosteroids are not routine: EASL 2019 says routine use 'may not be substantiated' (Grade C) and AASLD 2023 says they may be of benefit in selected patients, including those with severe hypersensitivity features or autoimmune features on biopsy. The sotorasib label is an exception: it says to consider systemic corticosteroids, and records hepatotoxicity in 40% of patients who had immunotherapy in the 3 months before starting against 17% of those never given it. On restarting, EASL considers controlled rechallenge justified in oncology (Grade B; 38% of 103 rechallenged pazopanib patients had a recurrence, none severe), AASLD says rechallenge should generally be avoided unless the benefit is high, and the tucatinib label warns of severe and fatal injury after rechallenge.
Four drugs read on 18 November 2026. Gilteritinib has no liver warning in either label: blood chemistries are assessed at least weekly for the first month, every other week for the second and then monthly in the US label, and on day 15 and then monthly in the EU SmPC; a grade 3 or higher toxicity considered related to treatment interrupts the drug until grade 1, resuming at 80 mg (US) or at 80 mg or 120 mg (EU). Olutasidenib (US label only): liver tests at least weekly for 2 months, every other week in the third month, once in the fourth and then every other month; grade 3 withholds with tests twice a week and a restart at 150 mg once daily; grade 4, or a Hy's law pattern with alkaline phosphatase below 2 times ULN and no clear other explanation, is a permanent stop. Enasidenib (US label only): its label says it may interfere with bilirubin metabolism through inhibition of UGT1A1; 89% of the patients whose bilirubin reached 2 times ULN had no accompanying transaminase rise, and the rule is a dose reduction to 50 mg daily, not a hold, when bilirubin stays above 3 times ULN for 2 weeks or more without raised transaminases or other hepatic disorders. Loncastuximab tesirine: the US label asks for liver tests at baseline and throughout treatment, withholds for a grade 3 or higher ALT or AST rise or suspected drug-induced liver injury and discontinues if that injury is confirmed; the EU SmPC has no liver warning and no liver row. A raised GGT on its own (57% in the US label, 21% at grade 3 or 4) falls under both labels' general row, which withholds at grade 3 or higher.
Why: Every label read asks for a test before treatment starts, and some (sotorasib, ribociclib) set their rules against the starting value when it was already raised.
“Monitor liver function tests (ALT, AST, alkaline phosphatase and total bilirubin) prior to the start of LUMAKRAS, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.”
Why: Each label sets its own timetable. The abemaciclib label gives a median time to a grade 3 or higher ALT rise of 57 to 87 days across four trials.
“Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.”
Eli Lilly, on DailyMed (US National Library of Medicine) 2026
Why: These are the signs the pazopanib patient information lists, with the words right away. The tucatinib, lapatinib and trastuzumab emtansine labels also list itching.
“Advise patients to report signs and symptoms of liver dysfunction to their healthcare provider right away”
Novartis, on DailyMed (US National Library of Medicine) 2025
Why: The FDA guidance, written for trials, calls this threshold reasonable because smaller rises are common and non-specific. It adds that results can go on worsening for days or weeks after the drug is stopped.
“It is critical to initiate close observation immediately upon detection and confirmation of early signals of possible DILI, and not to wait until the next scheduled visit or monitoring interval.”
Why: Repeat tests show whether the abnormality is improving or worsening, and the guidance treats a rising bilirubin or INR as a sign of substantial liver injury.
“Repeating liver enzyme and serum bilirubin tests two or three times weekly.”
Why: The history looks for another cause. Some combinations also add risk: the pazopanib label records more ALT rises when simvastatin is taken with it.
“Obtaining a history of concomitant drug use (including nonprescription medications and herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets.”
Why: AASLD recommends this for everyone with suspected drug injury, so that an acute viral hepatitis is not mistaken for it.
“Testing for acute viral hepatitis is recommended for all patients with suspected DILI including hepatitis A IgM, HBsAg, anti–hepatitis B core antibody IgM, and HCV RNA to exclude acute hepatitis C infection”
American Association for the Study of Liver Diseases (Hepatology) 2023
Why: In its section on checkpoint inhibitors, AASLD says recent studies suggest drug injury explains only 30% of demonstrable liver injury in advanced cancer; metastases, sepsis and other causes explain the rest.
“All patients with suspected DILI should undergo some type of liver imaging, typically starting with an abdominal ultrasound to assess for presence of cirrhosis, biliary obstruction, or other focal liver changes.”
American Association for the Study of Liver Diseases (Hepatology) 2023
Why: The pazopanib label continues treatment through an isolated ALT of 3 to 8 times normal. The FDA guidance says that in most people the liver appears able to adapt to a drug.
“Continue and monitor liver function weekly until ALT returns to Grade 1 or baseline.”
Novartis, on DailyMed (US National Library of Medicine) 2025
Why: The abemaciclib label withholds the drug until the rise is back to baseline or grade 1 and then resumes at the next lower dose; other labels set their own points.
“Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation”
Eli Lilly, on DailyMed (US National Library of Medicine) 2026
Why: Enzymes and bilirubin rising together signal a more serious injury. The FDA guidance cites studies in which about 10% of people with drug injury and jaundice died or needed a liver transplant.
“If patients develop ALT and/or AST > 3 x ULN along with total bilirubin > 2 x ULN irrespective of baseline grade, discontinue KISQALI.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: Pazopanib blocks the enzyme that clears bilirubin (UGT1A1), so indirect bilirubin can rise in people with Gilbert's syndrome. Its label then applies the rules for an isolated ALT rise.
“Patients with only a mild, indirect (unconjugated) hyperbilirubinemia, known as Gilbert’s syndrome, and ALT elevations > 3 × ULN should be managed per the recommendations outlined for isolated ALT elevations.”
Novartis, on DailyMed (US National Library of Medicine) 2025
Why: Neither label has a liver warning or a row for liver tests, and both say 'blood chemistries' without naming the tests. The rule is each label's general row, which interrupts until the toxicity resolves or improves to grade 1 and resumes at 80 mg (US) or at a reduced dose of 80 mg or 120 mg (EU). The US label records raised transaminases in 51% of 319 patients, grade 3 or higher in 21%.
“Assess blood counts and blood chemistries, including creatine phosphokinase, prior to the initiation of XOSPATA, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy.”
Astellas, on DailyMed (US National Library of Medicine) 2026
Why: This is the US label's rule; no EU product information was found. The label records liver toxicity in 23% of 153 patients, grade 3 or 4 in 13%. After a hold it resumes at 150 mg once daily; it is discontinued if grade 3 recurs at that dose, and permanently discontinued for grade 4 or for AST or ALT above 3 times normal with bilirubin above 2 times and alkaline phosphatase below 2 times normal with no clear other explanation.
“Withhold REZLIDHIA and monitor liver function tests, twice per week, until laboratory values have returned to baseline or Grade 1 toxicity.”
Rigel Pharmaceuticals, on DailyMed (US National Library of Medicine) 2025
Why: The US label says enasidenib may interfere with bilirubin metabolism through inhibition of UGT1A1. Bilirubin reached 2 times normal or more in 37% of 214 patients, and 89% of those had no accompanying transaminase rise or other severe liver event. The dose returns to 100 mg daily if bilirubin falls below 2 times normal. This is the US label; the EU application was withdrawn.
“Elevation of bilirubin greater than 3 times the upper limit of normal (ULN) sustained for ≥2 weeks without elevated transaminases or other hepatic disorders”
Celgene (Bristol Myers Squibb), on DailyMed (US National Library of Medicine) 2025
Why: The US label says cholestatic and hepatocellular liver injury, including fatal cases, has occurred. The EU SmPC has no liver warning and no liver row. A raised GGT (57% in the US label, 21% at grade 3 or 4) has no row of its own in either: at grade 3 or higher it falls under the row for other adverse reactions, which withholds until grade 1 or less.
“Monitor liver function tests at baseline and throughout treatment with ZYNLONTA.”
ADC Therapeutics, on DailyMed (US National Library of Medicine) 2026
Why: EASL finds routine steroid use unsupported (Grade C) and says steroids can be tried with marked hypersensitivity features or possible autoimmune hepatitis. AASLD says they may be of benefit in selected patients.
“In idiosyncratic DILI, routine use of corticosteroid treatment may not be substantiated.”
European Association for the Study of the Liver (Journal of Hepatology) 2019 · Grade C
Why: In the label's pooled lung cancer data, 64% of patients whose liver injury needed a dose change were given steroids. Liver injury occurred in 40% of those given immunotherapy in the 3 months before starting and in 17% of those never given it.
“Consider administering systemic corticosteroids for the management of hepatotoxicity.”
Why: The pazopanib label asks for weekly tests for 8 weeks after a restart and a permanent stop if ALT passes 3 times normal again. The tucatinib label also asks for weekly tests after a restart.
“If the potential benefit for resuming treatment with VOTRIENT is considered to outweigh the risk for hepatotoxicity, then resume at a reduced dose of no more than 400 mg once daily and measure serum liver tests weekly for 8 weeks.”
Novartis, on DailyMed (US National Library of Medicine) 2025
Why: AASLD says people with abnormal clotting or mental status changes may require hospitalisation, and puts survival without a transplant in drug-related acute liver failure at only 25%.
“Because of the low likelihood of spontaneous survival in idiosyncratic DILI-related ALF of only 25%, early transfer of these individuals to a liver transplant center is recommended.”
American Association for the Study of Liver Diseases (Hepatology) 2023
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
A baseline test, then tests on the label's own schedule; from ALT or AST above 3 times ULN, close observation with repeat tests two or three times a week, a medicines, supplement and alcohol history, viral serology and liver imaging (FDA guidance 2009, AASLD 2023, EASL 2019 Grade B for ultrasound in all suspected cases); hold, reduce and stop by the product label; permanent stop for a Hy's law case with no other cause. Where the sources differ they are all shown. Hold thresholds: pazopanib continues to 8 times ULN, ribociclib and vorasidenib are interrupted from grade 2, abemaciclib for persistent or recurrent grade 2 or for grade 3, tucatinib from grade 3, sotorasib above 5 times ULN or above 3 and up to 5 times with symptoms; the FDA trial guidance suggests considering a stop above 8 times ULN, or above 5 times for more than 2 weeks. A Hy's law pattern: permanent stop in most labels, but a reduced dose after a first occurrence in the vorasidenib label. Steroids: not routine (EASL Grade C; AASLD for selected cases; ACG calls their role controversial), but to be considered on sotorasib (label). Rechallenge: justified in oncology under control (EASL Grade B), generally to be avoided unless the benefit is high (AASLD), not above 5 times ULN in trials (FDA), never after severe changes on lapatinib (label).
European Association for the Study of the Liver (Journal of Hepatology) 2019 · American Association for the Study of Liver Diseases (Hepatology) 2023 · US Food and Drug Administration (CDER, CBER) 2009 · American College of Gastroenterology (American Journal of Gastroenterology) 2021 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2025 · Amgen, on DailyMed (US National Library of Medicine) 2026 · Seagen, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Servier, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026
Where it differs: After a baseline test: ribociclib every 2 weeks for the first 2 cycles, then at the start of each of the next 4 cycles. Abemaciclib every 2 weeks for 2 months, then monthly for 2 months. Tucatinib every 2 weeks for 2 months, then every 3 weeks during treatment. Pazopanib at weeks 3, 5, 7 and 9, at month 3 and month 4, then periodically. Sotorasib every 3 weeks for 3 months, then monthly. Adagrasib monthly for 3 months. Selpercatinib every 2 weeks for 3 months, then monthly. Vorasidenib every 2 weeks for 2 months, then monthly for the first 2 years. Ponatinib at least monthly. Lapatinib every 4 to 6 weeks. Trastuzumab emtansine and trabectedin before each dose.
Evidence: No label read compares one schedule with another; each records when rises were seen in its own trials. The pazopanib label records that 92% of transaminase rises of any grade came in the first 18 weeks; the ribociclib label gives a median onset of grade 3 or higher rises of 92 days in advanced breast cancer; the vorasidenib label a median first onset of 57 days with a range of 1 to 1049 days.
Novartis, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Seagen, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2025 · Amgen, on DailyMed (US National Library of Medicine) 2026 · Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Servier, on DailyMed (US National Library of Medicine) 2026 · Takeda, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Genentech, on DailyMed (US National Library of Medicine) 2026 · Janssen, on DailyMed (US National Library of Medicine) 2026
Where it differs: Pazopanib: continue with weekly tests for an isolated ALT between 3 and 8 times ULN; withhold above 8 times. Ribociclib: no change at grade 1; at grade 2 (more than 3 to 5 times ULN) interrupt if the baseline was below grade 2; at grade 3 interrupt and resume one dose level lower, and stop if grade 3 recurs. Abemaciclib: no change at grade 1 or a first grade 2; withhold for persistent or recurrent grade 2 or for grade 3. Tucatinib: hold at grade 3 and repeat tests within 48 to 72 hours, then consider a permanent stop or resume one dose level lower after recovery. Sotorasib: withhold above 5 times ULN, or above 3 and up to 5 times with symptoms, with the thresholds counted from baseline if the baseline was abnormal. Vorasidenib: weekly tests at grade 1; withhold at grade 2, resuming at the same dose if recovery takes 28 days or less.
Evidence: Regulatory labels, from each drug's own trials; no trial compares thresholds. The FDA's guidance for trials offers a general guide (consider stopping above 8 times ULN, above 5 times for more than 2 weeks, or above 3 times with symptoms or with bilirubin above 2 times ULN or INR above 1.5) and says it has not been tested prospectively.
Novartis, on DailyMed (US National Library of Medicine) 2025 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Seagen, on DailyMed (US National Library of Medicine) 2026 · Amgen, on DailyMed (US National Library of Medicine) 2026 · Servier, on DailyMed (US National Library of Medicine) 2026 · US Food and Drug Administration (CDER, CBER) 2009
Where it differs: For ALT or AST above 3 to 20 times ULN with total bilirubin above 2 times ULN, the vorasidenib label withholds the drug until recovery and resumes at a reduced dose on a first occurrence, stopping permanently only on recurrence. The sotorasib and adagrasib labels stop permanently only if no alternative cause is found; if another cause is identified, sotorasib is not resumed until the tests are back to baseline. The trastuzumab emtansine dose table stops permanently in the absence of another likely cause, such as liver metastasis or another medicine. Ribociclib, abemaciclib, tucatinib and pazopanib are stopped permanently.
Evidence: Regulatory labels. The vorasidenib label reports two patients who met the laboratory criteria for Hy's law, with autoimmune hepatitis and hepatic failure. AASLD's table defines Hy's law with a bilirubin above 2.5 mg/dl rather than 2 times ULN and gives it a positive predictive value of 8% to 20% for transplant or death.
Servier, on DailyMed (US National Library of Medicine) 2026 · Amgen, on DailyMed (US National Library of Medicine) 2026 · Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Eli Lilly, on DailyMed (US National Library of Medicine) 2026 · Seagen, on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2025 · Genentech, on DailyMed (US National Library of Medicine) 2026 · American Association for the Study of Liver Diseases (Hepatology) 2023
Where it differs: The sotorasib label says to consider systemic corticosteroids; no other label read does.
Evidence: In the label's pooled lung cancer population, 64% of patients whose hepatotoxicity needed a dose change were given corticosteroids, and 94% of events improved or resolved with dose changes, with or without steroids. Hepatotoxicity occurred in 40% of those given immunotherapy within 3 months before starting, 18% of those starting later and 17% of those never given it. The label gives no steroid dose and reports no controlled comparison.
Where it differs: EASL considers controlled rechallenge justified in oncology; AASLD says it should generally be avoided unless the expected benefit is high for a severe or life-threatening condition; the FDA trial guidance says generally not after rises above 5 times ULN; the lapatinib label says not to restart after severe changes; the tucatinib label carries a warning of severe and fatal hepatotoxicity, particularly after rechallenge.
Evidence: EASL cites a pooled analysis of pazopanib trials: of 103 patients rechallenged, 62 (60%) adapted and 39 (38%) had a recurrence, none severe. The tucatinib label reports five confirmed Hy's law cases in HER2CLIMB-05, one fatal, all after rechallenge.
European Association for the Study of the Liver (Journal of Hepatology) 2019 · American Association for the Study of Liver Diseases (Hepatology) 2023 · US Food and Drug Administration (CDER, CBER) 2009 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Seagen, on DailyMed (US National Library of Medicine) 2026
Where it differs: Gilteritinib: the US label assesses blood chemistries before starting, at least weekly for the first month, every other week for the second month and monthly after; the EU SmPC before starting, on day 15 and monthly. Both interrupt for other grade 3 or higher toxicity considered related to treatment until it resolves or improves to grade 1; the US label resumes at 80 mg, the EU SmPC at a reduced dose of 80 mg or 120 mg, because it allows a dose of 200 mg. Olutasidenib (US label; no EU text found): liver tests at least weekly for two months, every other week for the third, once in the fourth, then every other month; grade 3 withholds, with tests twice a week, and resumes at 150 mg once daily; grade 4 or a Hy's law pattern is a permanent stop. Enasidenib (US label; EU application withdrawn): no liver test timetable of its own; bilirubin above 3 times ULN for 2 weeks or more without raised transaminases or other hepatic disorders means a dose reduction to 50 mg daily, returning to 100 mg daily if it falls below 2 times ULN. Loncastuximab tesirine: the US label has a warning on liver injury, asks for liver tests at baseline and throughout treatment, withholds for a grade 3 or higher ALT or AST rise or suspected drug-induced liver injury and discontinues if that injury is confirmed; the EU SmPC has no liver warning and no liver row, only the general row that withholds for other adverse reactions of grade 3 or higher until grade 1 or less.
Evidence: Regulatory labels. Gilteritinib: the EU SmPC lists ALT increased in 82.1% and AST increased in 80.6%, and the US label lists transaminase increased in 51%. Olutasidenib: median onset of liver toxicity 1.2 months, range 1 day to 17.5 months; one patient given it with azacitidine, a combination for which it is not indicated, died from complications of drug-induced liver injury. Enasidenib: no patient needed a dose reduction for raised bilirubin, 3.7% had treatment interrupted and 1.4% stopped for good. Loncastuximab tesirine: the EU SmPC records that a raised GGT led to dose delay in 17.7%, dose reduction in 3.3% and treatment withdrawal in 8.8%.
Astellas, on DailyMed (US National Library of Medicine) 2026 · Astellas, on the European Medicines Agency website 2024 · Rigel Pharmaceuticals, on DailyMed (US National Library of Medicine) 2025 · Celgene (Bristol Myers Squibb), on DailyMed (US National Library of Medicine) 2025 · ADC Therapeutics, on DailyMed (US National Library of Medicine) 2026 · Swedish Orphan Biovitrum, on the European Medicines Agency website 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Routine corticosteroids are not supported in idiosyncratic drug-induced liver injury “In idiosyncratic DILI, routine use of corticosteroid treatment may not be substantiated.” | Grade C | European Association for the Study of the Liver (Journal of Hepatology) 2019 |
| Corticosteroids may help selected patients, such as those with severe hypersensitivity or autoimmune features “Corticosteroids given for 1–3 months may be of benefit in selected patients with idiosyncratic DILI, including those with severe hypersensitivity features, DRESS, and autoimmune features on liver biopsy.” | Guidance statement (consensus, not graded) | American Association for the Study of Liver Diseases (Hepatology) 2023 |
| The role of systemic corticosteroids is controversial “The role of systemic corticosteroids is controversial, but they may be administered when a liver injury event cannot be distinguished between autoimmune hepatitis or DILI or when a DILI event presents with prominent autoimmune hepatitis features.” | Not stated in the abstract | American College of Gastroenterology (American Journal of Gastroenterology) 2021 |
| Controlled rechallenge is considered justified in oncology “as they generally do not result in severe recurrence of hepatotoxicity. Grade B.” | Grade B | European Association for the Study of the Liver (Journal of Hepatology) 2019 |
| Rechallenge should generally be avoided unless the expected benefit is high “Rechallenge with the suspect drug should generally be avoided unless the anticipated benefit is high for a severe or life-threatening condition.” | Guidance statement (consensus, not graded) | American Association for the Study of Liver Diseases (Hepatology) 2023 |
| Rechallenge after rises above 5 times ULN should generally not be attempted (trials) “Generally, rechallenge of subjects with significant AT elevations (>5xULN) should not be” | Nonbinding recommendation | US Food and Drug Administration (CDER, CBER) 2009 |
| Abdominal ultrasound in everyone with suspected drug-induced liver injury “An abdominal ultrasound should be undertaken in all” | Grade B | European Association for the Study of the Liver (Journal of Hepatology) 2019 |
| Stopping the suspect drug and supportive care are the mainstay of management “Discontinuation of the suspect drug along with supportive care of antiemetics, antipruritics, and hydration are the mainstay of idiosyncratic DILI management.” | Guidance statement (consensus, not graded) | American Association for the Study of Liver Diseases (Hepatology) 2023 |
| Other causes, and a blocked bile duct, must be ruled out before a case counts under Hy's law “It is critical to rule out other causes of injury (e.g., other drugs or viral hepatitis) and to rule out an obstructive basis for the elevated bilirubin, so that alkaline phosphatase (ALP) should not be substantially elevated.” | Nonbinding recommendation | US Food and Drug Administration (CDER, CBER) 2009 |
| Stop tucatinib permanently for grade 4 enzymes or bilirubin; hold at grade 3 and retest in 48 to 72 hours “Hold TUKYSA and repeat testing within 48-72 hours to determine if worsening.” | Regulatory label; not graded | Seagen, on DailyMed (US National Library of Medicine) 2026 |
| Lapatinib is not restarted after severe liver test changes “If changes in liver function are severe, therapy with TYKERB should be discontinued and patients should not be retreated with TYKERB” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2026 |
| Trastuzumab emtansine: tests before every dose “Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose.” | Regulatory label; not graded | Genentech, on DailyMed (US National Library of Medicine) 2026 |
| Ponatinib: tests at baseline and at least monthly “Monitor liver function tests at baseline, then at least monthly or as clinically indicated.” | Regulatory label; not graded | Takeda, on DailyMed (US National Library of Medicine) 2026 |
| Selpercatinib: every 2 weeks for 3 months, then monthly “Monitor ALT and AST prior to initiating RETEVMO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated.” | Regulatory label; not graded | Eli Lilly, on DailyMed (US National Library of Medicine) 2026 |
| Adagrasib: monthly for 3 months “Monitor liver laboratory tests (AST, ALT, alkaline phosphatase and total bilirubin) prior to the start of KRAZATI and monthly for 3 months or as clinically indicated, with more frequent testing in patients who develop transaminase elevations.” | Regulatory label; not graded | Mirati Therapeutics, on DailyMed (US National Library of Medicine) 2026 |
| Trabectedin: tests before each administration “Assess LFTs prior to each administration of YONDELIS and as clinically indicated based on underlying severity of pre-existing hepatic impairment.” | Regulatory label; not graded | Janssen, on DailyMed (US National Library of Medicine) 2026 |
| Ribociclib: every 2 weeks for the first 2 cycles, then at the start of each of the next 4 cycles “Monitor LFTs every 2 weeks for first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2026 |
| Vorasidenib: every 2 weeks for 2 months, then monthly for the first 2 years “Monitor liver laboratory tests (AST, ALT, GGT, total bilirubin and alkaline phosphatase) prior to the start of VORANIGO, every 2 weeks during the first 2 months of treatment, then monthly for the first 2 years of treatment, and as clinically indicated, with more frequent testing in patients who develop transaminase elevations.” | Regulatory label; not graded | Servier, on DailyMed (US National Library of Medicine) 2026 |
| Pazopanib: weeks 3, 5, 7 and 9, months 3 and 4, then periodically “Monitor liver tests at baseline; at Weeks 3, 5, 7, and 9; at Month 3 and Month 4; and then periodically as clinically indicated.” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2025 |
| Gilteritinib (EU SmPC): blood chemistries before starting, on day 15 and monthly “Blood chemistries, including creatine phosphokinase, should be assessed prior to initiation of treatment, on day 15 and monthly for the duration of treatment” | Regulatory label; not graded | Astellas, on the European Medicines Agency website 2024 |
| Gilteritinib (US label): interrupt for other grade 3 or higher toxicity considered related to treatment “Interrupt XOSPATA until toxicity resolves or improves to Grade 1.” | Regulatory label; not graded | Astellas, on DailyMed (US National Library of Medicine) 2026 |
| Olutasidenib: liver tests at least weekly for two months, every other week for the third, once in the fourth, then every other month “Obtain baseline liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months, once every other week for the third month, once in the fourth month, and once every other month for the duration of therapy.” | Regulatory label; not graded | Rigel Pharmaceuticals, on DailyMed (US National Library of Medicine) 2025 |
| Olutasidenib: after a hold for grade 3, resume at 150 mg once daily “Resume REZLIDHIA at a reduced dose of 150 mg once daily and continue monitoring; may increase to 150 mg twice daily if hepatotoxicity resolves to baseline for at least 28 days.” | Regulatory label; not graded | Rigel Pharmaceuticals, on DailyMed (US National Library of Medicine) 2025 |
| Enasidenib may interfere with bilirubin metabolism through inhibition of UGT1A1 “IDHIFA may interfere with bilirubin metabolism through inhibition of UGT1A1” | Regulatory label; not graded | Celgene (Bristol Myers Squibb), on DailyMed (US National Library of Medicine) 2025 |
| Enasidenib: reduce the dose to 50 mg daily for a sustained, isolated bilirubin rise “Reduce IDHIFA dose to 50 mg daily.” | Regulatory label; not graded | Celgene (Bristol Myers Squibb), on DailyMed (US National Library of Medicine) 2025 |
| Enasidenib: patients are told the bilirubin rise is due to the drug's mechanism of action and not to liver damage “Inform patients that taking IDHIFA may cause elevated blood bilirubin, which is due to its mechanism of action, and not due to liver damage.” | Regulatory label; not graded | Celgene (Bristol Myers Squibb), on DailyMed (US National Library of Medicine) 2025 |
| Loncastuximab tesirine (US label): withhold for suspected drug-induced liver injury or a grade 3 or higher ALT or AST rise; discontinue on confirmation “Upon confirmation of DILI, discontinue ZYNLONTA.” | Regulatory label; not graded | ADC Therapeutics, on DailyMed (US National Library of Medicine) 2026 |
| Loncastuximab tesirine (EU SmPC): a raised GGT led to dose delay, dose reduction and treatment withdrawal “GGT increase resulted in dose delay, dose reduction, and treatment withdrawal in 17.7%, 3.3%, and 8.8% of patients, respectively.” | Regulatory label; not graded | Swedish Orphan Biovitrum, on the European Medicines Agency website 2026 |
Shares CTCAE toxicity grading (grade 3-4 adverse events), Ribociclib, Sotorasib, Abemaciclib.
Shares Olutasidenib, Enasidenib, Vorasidenib.
Shares CTCAE toxicity grading (grade 3-4 adverse events), Hepatotoxicity (liver enzyme elevation).
Shares Hepatic dose adjustment of anticancer drugs in reduced liver function, Hepatotoxicity (liver enzyme elevation).
Shares Olutasidenib, Enasidenib, Gilteritinib.
Shares Olutasidenib, Enasidenib, Gilteritinib.